Combination Thyroid Hormone Replacement; Knowns and Unknowns
Open accessThe DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Abstract
Hypothyroidism is common throughout the world and readily diagnosed with thyroid function tests. Management should be straightforward but appears not to be the case. Thyroid hormone replacement with levothyroxine monotherapy is the standard treatment which is effective in the majority of cases. However, 10-15% of patients established on levothyroxine do not feel their health is entirely restored and some patients prefer the addition of liothyronine. Proponents of liothyronine argue that the ratio of T3 and T4 hormones is substantially altered on T4 monotherapy and therefore both hormones may be needed for optimal health. This remains controversial as clinical trials have not demonstrated superiority of combination therapy (levothyroxine and liothyronine) over levothyroxine monotherapy. There is now a pressing need for further studies and in particular randomized controlled trials in this area. To help design and facilitate dedicated trials and better understand thyroid hormone replacement, this review summarizes the evidence where there is established knowledge and agreement (knowns) and areas where research is lacking (unknowns). Agreements include the extent of dissatisfaction with levothyroxine monotherapy, biases in testing for hypothyroidism and prescribing levothyroxine, as well as variable thresholds for prescribing levothyroxine and challenges in liothyronine dosing. The review will also highlight and summarize the unknowns including the long-term safety profile of liothyronine, and potential biomarkers to identify individuals who might benefit most from combination therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Global epidemiology of hyperthyroidism and hypothyroidism
Taylor, P. N., Albrecht, D., Scholz, A., Gutierrez-Buey, G., Lazarus, J. H., Dayan, C. M., & Okosieme, O. E. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.18 · Cited by 1,552
Self-citationChaker, L., Bianco, A. C., Jonklaas, J., & Peeters, R. P. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30703-1 · Cited by 1,159
Andersen, S., Pedersen, K. M., Bruun, N. H., & Laurberg, P. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.3.8165 · Cited by 686
Saravanan, P., Chau, W. ‐., Roberts, N., Vedhara, K., Greenwood, R., & Dayan, C. M. (2002) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2002.01654.x · Cited by 514
Self-citationThyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism
Stott, D. J., Rodondi, N., Kearney, P. M., Ford, I., Westendorp, R. G. J., Mooijaart, S. P., Sattar, N., Aubert, C. E., Aujesky, D., Bauer, D. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1603825 · Cited by 490 · cited 1×
“For instance, individuals with non-specific symptoms and borderline or normal thyroid function (prior to treatment)may have little to gain from either LT4 or combination LT3:LT4 therapy (47, 48).”
BackgroundConversion of Thyroxine (T4) to triiodothyronine (T3) in athyreotic human subjects
Braverman, L. E., Ingbar, S. H., & Sterling, K. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106304 · Cited by 485 · cited 3×
“The concentration of circulating T4 is about five times higher than T3 and it is the circulating T4 rather than T3 that serves as the main source of thyroid hormone for the body (5).”
BackgroundInfluentialBunevičius, R., Kažanavičius, G., Žalinkevičius, R., & Prange, A. J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199902113400603 · Cited by 482
2012 ETA Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism
Wiersinga, W. M., Duntas, L., Fadeyev, V., Nygaard, B., & Vanderpump, M. P. J. (2012) · European Thyroid Journal · doi:10.1159/000339444 · Cited by 437 · cited 4×
“Using these recommended ratios (26) a patient on 100 mcg of LT4 would require between 4 and 6 mcg of LT3 which would be impractical to deliver in split doses with current LT3 formulations.”
BackgroundInfluentialFlynn, R. W., Bonellie, S. R., Jung, R. T., MacDonald, T. M., Morris, A. D., & Leese, G. P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1625 · Cited by 415
A Mutation in the Thyroid Hormone Receptor Alpha Gene
Bochukova, E., Schoenmakers, N., Agostini, M., Schoenmakers, E., Rajanayagam, O., Keogh, J. M., Henning, E., Reinemund, J., Gevers, E., Sarri, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110296 · Cited by 379 · cited 2×
“The potential for dichotomy between serum thyroid hormone levels and intracellular action is dramatically illustrated in reports of individuals with rare mutations in the MCT8 transporter (Allan-HerndonDudley syndrome) or the thyroid hormone receptor alpha (present in many tissues but not the hypothalamus/pituitary) (…”
BackgroundPanicker, V., Saravanan, P., Vaidya, B., Evans, J., Hattersley, A. T., Frayling, T. M., & Dayan, C. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1301 · Cited by 327
Self-citationLevothyroxine Monotherapy Cannot Guarantee Euthyroidism in All Athyreotic Patients
Gullo, D., Latina, A., Frasca, F., Le Moli, R., Pellegriti, G., & Vigneri, R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022552 · Cited by 307 · cited 3×
“LT4 monotherapy results in individuals having relatively lower FT3 and higher FT4 levels than individuals with an intact, undisturbed, hypothalamopituitary-thyroid (HPT) axis (13), but the clinical relevance of this finding is controversial (14).”
BackgroundTaylor, P. N., Iqbal, A., Minassian, C., Sayers, A., Draman, M. S., Greenwood, R., Hamilton, W., Okosieme, O., Panicker, V., Thomas, S. L., et al. (2014) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.11312 · Cited by 300
Self-citationWekking, E. M., Appelhof, B. C., Fliers, E., Schene, A. H., Huyser, J., Tijssen, J. G. P., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02025 · Cited by 299
Grozinsky-Glasberg, S., Fraser, A., Nahshoni, E., Weizman, A., & Leibovici, L. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0448 · Cited by 296
Escobar-Morreale, H. F., Obregón, M. J., Escobar del Rey, F., & Morreale de Escobar, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118353 · Cited by 287
Genome-wide analyses identify a role for SLC17A4 and AADAT in thyroid hormone regulation
Teumer, A., Chaker, L., Groeneweg, S., Li, Y., Di Munno, C., Barbieri, C., Schultheiss, U. T., Traglia, M., Ahluwalia, T. S., Akiyama, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06356-1 · Cited by 280
A Review of the Clinical Consequences of Variation in Thyroid Function Within the Reference Range
Taylor, P. N., Razvi, S., Pearce, S. H., & Dayan, C. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1315 · Cited by 274 · cited 1×
“Given the importance of thyroid status for health (90) and the substantial dissatisfaction with LT4 replacement (8)”
BackgroundSelf-citationPeeters, R. P., Wouters, P. J., van Toor, H., Kaptein, E., Visser, T. J., & Van den Berghe, G. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0535 · Cited by 251 · cited 1×
“Second, by contrast, during acute illness T3 falls rapidly whereas T4 is maintained, or may even rise (82).”
BackgroundMeyerovitch, J. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.14.1533 · Cited by 245
An Online Survey of Hypothyroid Patients Demonstrates Prominent Dissatisfaction
Peterson, S. J., Cappola, A. R., Castro, M. R., Dayan, C. M., Farwell, A. P., Hennessey, J. V., Kopp, P. A., Ross, D. S., Samuels, M. H., Sawka, A. M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0681 · Cited by 231 · cited 4×
“Increased awareness and self-medication with LT3 has also been observed in Denmark (20) and the USA (8).”
BackgroundInfluentialSelf-citationWalsh, J. P., Shiels, L., Lim, E. M., Bhagat, C. I., Ward, L. C., Stuckey, B. G. A., Dhaliwal, S. S., Chew, G. T., Bhagat, M. C., & Cussons, A. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030249 · Cited by 210
Okosieme, O., Gilbert, J., Abraham, P., Boelaert, K., Dayan, C., Gurnell, M., Leese, G., McCabe, C., Perros, P., Smith, V., et al. (2016) · Clinical Endocrinology · doi:10.1111/cen.12824 · Cited by 208 · cited 1×
“Likewise, a British Thyroid Association position statement also endorses LT4 as the treatment of choice but acknowledges that a trial of combination therapy could be warranted in patients who have unequivocally failed to respond to LT4 following a discussion with the patient of the uncertain risks and benefits of comb…”
BackgroundSelf-citationHadlow, N. C., Rothacker, K. M., Wardrop, R., Brown, S. J., Lim, E. M., & Walsh, J. P. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4223 · Cited by 203
Pilo, A., Iervasi, G., Vitek, F., Ferdeghini, M., Cazzuola, F., & Bianchi, R. (1990) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1990.258.4.e715 · Cited by 185
Werneck de Castro, J. P., Fonseca, T. L., Ueta, C. B., McAninch, E. A., Abdalla, S., Wittmann, G., Lechan, R. M., Gereben, B., & Bianco, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci77588 · Cited by 184 · cited 4×
“Normalization of tissue thyroid status in murine studies was achieved using slow release pellets of T4 and T3 (25).”
BackgroundInfluentialAppelhof, B. C., Fliers, E., Wekking, E. M., Schene, A. H., Huyser, J., Tijssen, J. G. P., Endert, E., van Weert, H. C. P. M., & Wiersinga, W. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2111 · Cited by 183
Is a Normal TSH Synonymous With “Euthyroidism” in Levothyroxine Monotherapy?
Peterson, S. J., McAninch, E. A., & Bianco, A. C. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2660 · Cited by 182 · cited 3×
“Prolonged exposure to this different ratio appeared to have adverse health outcomes as, LT4 treated individuals had higher a body mass index despite lower calorie consumption, reported less physical activity and were more likely to be taking antidepressants (14), although confounding remains a possibility.”
BackgroundResultEscobar-Morreale, H. F., Botella-Carretero, J. I., Gómez-Bueno, M., Galán, J. M., Barrios, V., & Sancho, J. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-6-200503150-00007 · Cited by 182
Do traditional symptoms of hypothyroidism correlate with biochemical disease?
Canaris, G. J., Steiner, J. F., & Ridgway, E. C. (1997) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.1997.07109.x · Cited by 172
Leese, G. P., Flynn, R. V., Jung, R. T., MacDonald, T. M., Murphy, M. J., & Morris, A. D. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2007.03051.x · Cited by 165
Gastrointestinal malabsorption of thyroxine
Virili, C., Antonelli, A., Santaguida, M. G., Benvenga, S., & Centanni, M. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00168 · Cited by 164 · cited 1×
“, iron supplements) timing of medication (ingestion of caffeine around the time of T4 will impair absorption) (56, 57).”
BackgroundTreatment of Hypothyroidism with Combinations of Levothyroxine plus Liothyronine
Escobar-Morreale, H. F., Botella-Carretero, J. I., del Rey, F. E., & de Escobar, G. M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0184 · Cited by 160
Nygaard, B., Jensen, E. W., Kvetny, J., Jarløv, A., & Faber, J. (2009) · European Journal of Endocrinology · doi:10.1530/eje-09-0542 · Cited by 153
Watt, T., Cramon, P., Hegedüs, L., Bjorner, J. B., Bonnema, S. J., Rasmussen, Å. K., Feldt-Rasmussen, U., & Groenvold, M. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1322 · Cited by 152 · cited 5×
“Potentially more robust disease-specific patient reported outcomes such as THYPRO are now available (40).”
BackgroundInfluentialHoang, T. D., Olsen, C. H., Mai, V. Q., Clyde, P. W., & Shakir, M. K. M. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4107 · Cited by 151
Ito, M., Miyauchi, A., Morita, S., Kudo, T., Nishihara, E., Kihara, M., Takamura, Y., Ito, Y., Kobayashi, K., Miya, A., et al. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-1029 · Cited by 133
Panicker, V., Evans, J., Bjøro, T., Åsvold, B. O., Dayan, C. M., & Bjerkeset, O. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03521.x · Cited by 121
Self-citationChristoffolete, M. A., Ribeiro, R., Singru, P., Fekete, C., da Silva, W. S., Gordon, D. F., Huang, S. A., Crescenzi, A., Harney, J. W., Ridgway, E. C., et al. (2006) · Endocrinology · doi:10.1210/en.2005-1300 · Cited by 118
The history and future of treatment of hypothyroidism
McAninch, E. A., & Bianco, A. C. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1799 · Cited by 118
Changes in the prevalence of hypothyroidism: the HUNT Study in Norway
Åsvold, B. O., Vatten, L. J., & Bjøro, T. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0459 · Cited by 118
Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism
Wiersinga, W. M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.258 · Cited by 114 · cited 1×
“The most pertinent issue is that there are widespread reports of dissatisfaction with LT4 replacement (8) estimated at 10–15% of patients (2, 9).”
BackgroundDiagnosis and management of treatment-refractory hypothyroidism: an expert consensus report
Centanni, M., Benvenga, S., & Sachmechi, I. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0706-y · Cited by 113
Smith, R. N., Taylor, S. A., & Massey, J. C. (1970) · BMJ · doi:10.1136/bmj.4.5728.145 · Cited by 106 · cited 1×
“It is worth noting that one of the key early studies which favored LT4 monotherapy in terms of patient preference over LT3:LT4 combination treatment (71) used up to 60 mcg of LT3 a day.”
ResultWhole-genome sequence-based analysis of thyroid function
Taylor, P. N., Porcu, E., Chew, S., Campbell, P. J., Traglia, M., Brown, S. J., Mullin, B. H., Shihab, H. A., Min, J., Walter, K., et al. (2015) · Nature Communications · doi:10.1038/ncomms6681 · Cited by 104 · cited 2×
“It is wellestablished that intra-individual variation in thyroid hormone levels is much narrower than inter-individual variation (62) and that thyroid hormone levels in healthy adult individuals are largely genetically determined (59, 61).”
BackgroundSelf-citationSaravanan, P., Siddique, H., Simmons, D., Greenwood, R., & Dayan, C. (2007) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2007-973071 · Cited by 100
Self-citationPollock, M. A., Sturrock, A., Marshall, K., Davidson, K. M., Kelly, C. J. G., McMahon, A. D., & McLaren, E. H. (2001) · BMJ · doi:10.1136/bmj.323.7318.891 · Cited by 98
Adequacy of thyroid hormone replacement in a general population
Okosieme, O. E., Belludi, G., Spittle, K., Kadiyala, R., & Richards, J. (2011) · QJM · doi:10.1093/qjmed/hcq222 · Cited by 96 · cited 1×
“Consistently many patients (∼20%) may be apparently “overreplaced” with LT4 as evidenced by a low or suppressed TSH (11, 15, 16).”
BackgroundSelf-citationCarlé, A., Faber, J., Steffensen, R., Laurberg, P., & Nygaard, B. (2017) · European Thyroid Journal · doi:10.1159/000469709 · Cited by 93 · cited 2×
“Individuals with genetic variants in DIO2 (rs225014) (80) and MCT10 (rs12885300) (77) have shown preference for combination LT3:LT4 therapy with an additive effect (77).”
BackgroundThyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism
Chao, M., Jiawei, X., Xia, H., Guoming, W., Yangang, W., Xufu, W., & Shuyao, Z. (2009) · Nuclear Medicine Communications · doi:10.1097/mnm.0b013e32832c79e0 · Cited by 93
Saravanan, P., Visser, T. J., & Dayan, C. M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0414 · Cited by 90
Self-citationHoermann, R., Midgley, J. E. M., Giacobino, A., Eckl, W. A., Wahl, H. G., Dietrich, J. W., & Larisch, R. (2014) · Clinical Endocrinology · doi:10.1111/cen.12527 · Cited by 82 · cited 1×
“Studies of patients established on levothyroxine also reveal that the relationship between TSH and FT3 disassociates on LT4 monotherapy particularly in athyreotic individuals (13, 50, 53).”
BackgroundLiothyronine use in a 17 year observational population‐based study ‐ the tears study
Leese, G. P., Soto‐Pedre, E., & Donnelly, L. A. (2016) · Clinical Endocrinology · doi:10.1111/cen.13052 · Cited by 75 · cited 1×
“A recent observational study (87) of 400 patients on LT3 therapy (median duration of therapy 10.”
BackgroundThyroxine replacement: a clinical endocrinologist’s viewpoint
Eligar, V, Taylor, P., Okosieme, O., Leese, G., & Dayan, C. (2016) · Annals of Clinical Biochemistry: International Journal of Laboratory Medicine · doi:10.1177/0004563216642255 · Cited by 72
Self-citationMedici, B. B., Nygaard, B., la Cour, J. L., Grand, M. K., Siersma, V., Nicolaisdottir, D. R., Lind, B., Olivarius, N. D. F., & Andersen, C. L. (2019) · Thyroid® · doi:10.1089/thy.2018.0539 · Cited by 63
Dayan, C., & Panicker, V. (2018) · Thyroid Research · doi:10.1186/s13044-018-0045-x · Cited by 62
Self-citationMichaelsson, L. F., Medici, B. B., la Cour, J. L., Selmer, C., Røder, M., Perrild, H., Knudsen, N., Faber, J., & Nygaard, B. (2015) · European Thyroid Journal · doi:10.1159/000437262 · Cited by 57 · cited 1×
“Increased awareness and self-medication with LT3 has also been observed in Denmark (20) and the USA (8).”
BackgroundTaylor, P. N., Richmond, R., Davies, N., Sayers, A., Stevenson, K., Woltersdorf, W., Taylor, A., Groom, A., Northstone, K., Ring, S., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3505 · Cited by 48
Self-citationMassolt, E. T., van der Windt, M., Korevaar, T. I. M., Kam, B. L. R., Burger, J. W., Franssen, G. J. H., Lehmphul, I., Köhrle, J., Visser, W. E., & Peeters, R. P. (2016) · Clinical Endocrinology · doi:10.1111/cen.13101 · Cited by 47
Combined Thyroxine and Triiodothyronine for Thyroid Replacement Therapy
Taylor, S., Kapur, M., & Adie, R. (1970) · BMJ · doi:10.1136/bmj.2.5704.270 · Cited by 44 · cited 1×
“Even in the early 1970’s when traditionally higher treatment doses (150 mcg of LT4 and 45 mcg of LT3) were used and treatment initiated at more advanced disease stages, it was recognized that a subset of individuals required LT3 to restore health (35).”
MethodJonklaas, J., & Burman, K. D. (2016) · Thyroid® · doi:10.1089/thy.2015.0629 · Cited by 41
Taylor, P. N., Panicker, V., Sayers, A., Shields, B., Iqbal, A., Bremner, A. P., Beilby, J. P., Leedman, P. J., Hattersley, A. T., Vaidya, B., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0938 · Cited by 41
Self-citationTaylor, P. N., Sayers, A., Okosieme, O., Das, G., Draman, M. S., Tabasum, A., Abusahmin, H., Rahman, M., Stevenson, K., Groom, A., et al. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3605 · Cited by 34
Self-citationDew, R., King, K., Okosieme, O. E., Pearce, S. H., Donovan, G., Taylor, P. N., Hickey, J., Dayan, C. M., Leese, G., Razvi, S., et al. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019970 · Cited by 31
Self-citationDel Duca, S. C., Santaguida, M. G., Brusca, N., Gatto, I., Cellini, M., Gargano, L., Verga Falzacappa, C., Frattaroli, F. M., Virili, C., & Centanni, M. (2015) · European Journal of Endocrinology · doi:10.1530/eje-15-0314 · Cited by 31
Investigation of thyroid dysfunction is more likely in patients with high psychological morbidity
Bould, H., Panicker, V., Kessler, D., Durant, C., Lewis, G., Dayan, C., & Evans, J. (2012) · Family Practice · doi:10.1093/fampra/cmr059 · Cited by 29
Self-citationDa Conceição, R. R., Fernandes, G. W., Fonseca, T. L., Bocco, B. M. L. C., & Bianco, A. C. (2018) · Thyroid · doi:10.1089/thy.2018.0205 · Cited by 23 · cited 1×
“Long-acting T3 preparations are in development and may be the key here (68).”
Background
Cited by
Optimal thyroid hormone replacement
Jonklaas, J. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab031 · Cited by 89
Mitchell, A. L., Hegedüs, L., Žarković, M., Hickey, J. L., & Perros, P. (2021) · Clinical Endocrinology · doi:10.1111/cen.14340 · Cited by 81
Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?
Ettleson, M. D., & Bianco, A. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa430 · Cited by 75
Transplantable human thyroid organoids generated from embryonic stem cells to rescue hypothyroidism
Romitti, M., Tourneur, A., de Faria da Fonseca, B., Doumont, G., Gillotay, P., Liao, X.-H., Eski, S. E., Van Simaeys, G., Chomette, L., Lasolle, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34776-7 · Cited by 64
Metadata
- Authors
- Taylor, P. N., Eligar, V., Muller, I., Scholz, A., Dayan, C., & Okosieme, O.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-10-22
- Volume
- 10
- Pages
- 706-706
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2981931840
- Cited by
- 21
- References
- 68
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.